Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
← catalyst calendarNCT07190222 · readout in 1,196 d
Sponsored by Sanofi (industry) · SNY — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
942estimated
Sites
213
Countries
Argentina, Australia, Brazil +11
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-09-17 | actual | When the study began enrolling |
| Primary completion | 2029-11-27 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2030-01-22 | estimated | The whole study's end, after follow-up |
| First posted | 2025-09-24 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-15 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Chronic Obstructive Pulmonary Disease
Interventions
- Drug: Lunsekimig — also filed as SAR443765
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFAnnualized rate of moderate-to-severe chronic obstructive pulmonary disease (COPD) exacerbations
measured From Baseline up to 48 weeks
Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed